Ovata Capital Management’s Regenxbio RGNX Stock Holding History

Ovata Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-40,000	Closed	-$843K	–	48
2024 Q1	$843K	Buy	+40,000	New	+$712K	0.44%	28

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Ovata Capital Management's RGNX Position: Q2 2024 in Review

Ovata Capital Management sold out of Regenxbio (RGNX) in Q2 2024, closing a stake of 40,000 shares — an estimated $843K sold.

Ovata Capital Management first reported a position in RGNX in Q1 2024 and held it in 1 quarter. The position peaked at $843K in Q1 2024. 181 funds tracked by Wall St. Rank hold RGNX as of Q2 2024.

Ovata Capital Management reported no remaining Regenxbio position as of Q2 2024 after selling out during the quarter.
Ovata Capital Management sold 40,000 Regenxbio shares in Q2 2024, an estimated $843K.
Ovata Capital Management first reported a position in Regenxbio in Q1 2024 and held it in 1 quarter.
Ovata Capital Management's Regenxbio position peaked at $843K in Q1 2024.
181 funds tracked by Wall St. Rank held Regenxbio as of Q2 2024.

Based on Ovata Capital Management's 13F filing for Q2 2024, filed 5 Aug 2024.